SCHEMBL491285

SCHEMBL491285

COC(=O)Cc1cc(-c2ccc(Cl)cc2)cc(-c2ccc(C(F)(F)F)cc2)c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 10/20 0.49
PPARA Q07869 4/20 0.49
LMNA P02545 1/20 0.46
PTGDR2 Q9Y5Y4 1/20 0.46
PPARG P37231 2/20 0.46
CNR2 P34972 1/20 0.45
RXRA P19793 2/20 0.44
RXRB P28702 2/20 0.44
RXRG P48443 2/20 0.44
PSEN1 P49768 1/20 0.42
PSEN2 P49810 1/20 0.42
APH1B Q8WW43 1/20 0.42
NCSTN Q92542 1/20 0.42
APH1A Q96BI3 1/20 0.42
PSENEN Q9NZ42 1/20 0.42
HSP90AB1 P08238 1/20 0.42
CNR1 P21554 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5444853 0.93 PPARD (0.54) PPARDPPARALMNAPPARGRXRA
SCHEMBL491508 0.89 HSP90AB1 (0.51) PPARDHSP90AB1
SCHEMBL12703212 0.85 PPARD (0.47) PPARDPPARALMNAPPARGRXRA
SCHEMBL14477117 0.83 CYP4F2 (0.53) LMNARXRARXRBRXRGPSEN1
SCHEMBL6270689 0.81 AGXT (0.56) RXRAPSEN1PSEN2APH1BNCSTN
SCHEMBL478056 0.79 RXRA (0.48) PPARDPPARALMNAPPARGRXRA
SCHEMBL9926848 0.79 CYP11B1 (0.60) PPARDPPARALMNAPPARGRXRA
SCHEMBL29617616 0.79 CYP11B1 (0.60) PPARDPPARALMNAPPARGRXRA
SCHEMBL478341 0.79 SYK (0.48) PPARDPPARALMNAPPARGRXRA
SCHEMBL1843439 0.79 LMNA (0.47) PPARDLMNAHSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2016039-B1 TERPHENYL DERIVATIVES FOR TREATMENT OF ALZHEIMER' S DISEASE ORTHO MCNEIL JANSSEN PHARM (US) 2012-08-01 EP disclosed
US-8106236-B2 Triaryl compounds and derivates thereof ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2012-01-31 US disclosed
EP-1847524-B1 Terphenyl derivatives for treatment of Alzheimer's disease CELLZOME LTD (GB) 2009-10-14 EP disclosed
US-20070254957-A1 TRIARYL COMPOUNDS AND DERIVATES THEREOF ORTHO-MCNEIL PHARMACEUTICAL, INC. 2007-11-01 US disclosed
EP-1847524-A1 Terphenyl derivatives for treatment of Alzheimer's disease Cellzome (UK) Ltd. (GB) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254957-A1 TRIARYL COMPOUNDS AND DERIVATES THEREOF BACE1, BACE2, APP PPARD 488/4885PPARA 790/4885LMNA 1012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.